ER、PR以及Ki-67状态与乳腺癌新辅助化疗疗效的相关性

目的 探究雌激素受体(ER)、孕激素受体(PR)以及Ki67抗原(Ki67)状态与乳腺癌(BC)新辅助化疗疗效的相关性.方法 选取本院2015年12月至2020年5月216例乳腺癌患者,术前均进行新辅助化疗.采用免疫组织化学染色检测ER、PR、Ki-67,评价疗效,分析ER、PR、Ki-67与疗效的关系.结果 总有效率...

Correlation of ER,PR,and Ki-67 status with the efficacy of neoadjuvant chemotherapy for breast cancer

Objective To explore the correlation between estrogen receptor(ER),progesterone receptor(PR)and Ki67 antigen(Ki67 antigen,Ki67)status and the efficacy of neoadjuvant chemotherapy for breast cancer(BC).Methods From December 2015 to May 2020 in our hospital,216 breast cancer patients received neoadjuvant chemotherapy before surgery.Immunohistochemical staining was used to detect ER,PR,Ki-67;evaluate the efficacy;analyze the relationship between ER,PR,Ki-67 and the efficacy.Results The total effective rate was 87.04%(188/216),and the pathologic complete response(pCR)was 15.74%(34/216).The positive rate of ER and negative rate of PR increased after chemotherapy,and the difference was not statistically significant compared with before chemotherapy(P>0.05).The Ki-67 negative rate after chemotherapy was significantly higher than before chemotherapy,and the difference was statistically significant(P<0.05).There was no significant correlation between ER,PR,Ki-67 status and the efficacy of neoadjuvant chemotherapy(all P>0.05,r=0.632).The negative expression of ER was an independent factor predicting the pCR of neoadjuvant chemotherapy,and the difference was statistically significant(P<0.05).Conclusion There is no obvious relationship between PR and Ki-67 status and the efficacy of neoadjuvant chemotherapy for breast cancer.ER was negatively correlated with the efficacy of neoadjuvant chemotherapy.